Index: Epilepsia 30(4) , 422-9, (1989)
Full Text: HTML
This study evaluated the effects of cinromide in patients with Lennox-Gastaut Syndrome. No difference between cinromide and placebo was shown in terms of seizure reduction or global evaluations. This study is important, however, because it represents an effort to overcome methodologic difficulties inherent in evaluating this population, and because a substantial placebo response was demonstrated. The need for well-designed, placebo-controlled clinical studies of potential antiepileptic drugs, even in an especially refractory and mentally impaired population, is underscored by the study's outcome.
| Structure | Name/CAS No. | Molecular Formula | Articles |
|---|---|---|---|
![]() |
Cinromide
CAS:58473-74-8 |
C11H12BrNO |
|
Prediction of steady-state behavior of metabolite from dosin...
1980-05-01 [J. Pharm. Sci. 69(5) , 610-2, (1980)] |
|
Variability in the determination of fraction metabolized in ...
1984-02-01 [J. Pharm. Sci. 73(2) , 285-7, (1984)] |
|
Simultaneous determination of the anticonvulsants, cinromide...
[J. Chromatogr. A. 163(2) , 187-93, (1979)] |
|
The effect of cinromide on "kindled" seizures in the rat.
1982-03-01 [Neuropharmacology 21(3) , 273-6, (1982)] |
|
Fractions metabolized in a triangular metabolic system: cinr...
1985-08-01 [J. Pharmacokinet. Biopharm. 13(4) , 373-86, (1985)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved
